People’s Daily Online, Beijing, April 18th (Reporter Bao Congying) In order to accelerate the innovation of the pharmaceutical and health industry and help the development of new quality productivity, recently, nine departments such as the Beijing Medical Security Bureau and other departments jointly launched the “Beijing Municipality’s high -quality development measures for innovation pharmaceuticals (2024) “(hereinafter referred to as” several measures “), mobilize multi -departments to jointly develop from the policy level to form a multi -dimensional support for the development of the innovative pharmaceutical industry.
“Several measures” adhere to the people’s health needs and economic and social development as the starting point, and propose 32 measures from eight aspects including innovative pharmaceutical equipment research and development, clinical experiments, review approval, manufacturing, circulation trade, and clinical application.Research, production, trial, and full chain provide policy support, and promote the deep integration of the innovation chain, industrial chain and policy chain.It is clearly put forward such as: setting up ten areas or more areas or specialists, clinical research consortiums, compressed clinical experiments to start the overall time to 28 weeks, the approval time of drug clinical trials is reduced to 30 days, and ten varieties are promoted in the Beijing Tianzhu Comprehensive Bonded Area in Beijing Tianzhu Comprehensive Bonded AreaThe full chain opens up to the ground, innovative drug equipment has “followed the approval” according to clinical needs, and the number of hospital drugs is restricted according to clinical needs.Ensure that it provides key motivation and strategic starting point for the high -quality development of pharmaceutical health undertakings, and stimulates the overall vitality of innovative pharmaceutical companies.
At the same time, the “several measures” proposed that promoting Beijing -Tianjin -Hebei drugs and medical consumables for centralized procurement and hanging network information collaboration and sharing, continuously promoting Beijing -Tianjin -Hebei “3+N” drugs and medical consumables for centralized procurement cooperation, supporting innovative drugs in Beijing and Tianjin in Beijing and TianjinUse three places.It is reported that at present, Beijing -Tianjin -Hebei three places have relying on the “3+N” alliance mechanism, and 76 drugs and 8 types of consumables have been collected, which significantly reduces the medical burden of patients.
In addition, “several measures” proposed that Beijing will establish a dynamic adjustment mechanism for the “Beijing Inclusive Health Insurance” special medicine list, combined with the adjustment of national medical insurance and drug directory adjustments and special drugs, and the scope of dynamic adjustment and guarantee to ensure that the city’s innovative drugs are in the same conditions in the same conditions in the same condition.Priority to the scope of protection and support the development of the pharmaceutical and health industry in Beijing.
At present, Beijing has opened a “dual -channel” pilot to 35 fixed -point medical institutions and fixed -point retail pharmacies to ensure that the supply of drugs on national negotiations.The measures proposed that the scope of pilot medical institutions will be gradually expanded in accordance with the pilot situation, and strive to cover all secondary medical institutions above the end of 2024.
The proposal of “several measures” will enhance the confidence of Beijing pharmaceutical companies, stimulate innovation momentum, and inject a strong driving force into the development of new productive forces in Beijing.Relying on the implementation of measures, further improve the supply capacity of innovative drugs, promote the improvement of medical services, and enhance the sense of health in the masses; open up the blocking point of industrial innovation cycle, accelerate product research and development, clinical trials, review approval, manufacturing, and listing applications.Innovate the cycle, support the digital and intelligent upgrades of enterprises, and help innovate pharmaceutical companies to grow quickly and healthy; promote the coordinated development of the biopharmaceutical industry and insurance financial industry in Beijing, improve the use of innovative drug equipment and diversified payment systems, and effectively reduce the burden of medical expenses for the people.Continuously meet the growing health needs of the people.
Report/feedback
